Spark Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Spark Therapeutics, Inc.
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.
- Drug Delivery
- Site Specific
- Other Names / Subsidiaries
- Genable Technologies Limited
- Roche Holding AG (RHHBY)